FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1487-1493 May 22, 1997 Number 21 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In patients with advanced human immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can become extensive and debilitating. Preliminary reports suggest that thalidomide may promote the healing of oral aphthous ulcers.

Methods We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients. The patients received a four-week course of either 200 mg of thalidomide or placebo orally once per day. They were evaluated weekly for the condition of the ulcers, their quality of life, and evidence of toxicity. Assays were performed for plasma tumor necrosis factor (TNF-), soluble TNF- receptors, and HIV RNA.

Results Sixteen of 29 patients in the thalidomide group (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only 2 of 28 patients in the placebo group (7 percent; odds ratio, 15; 95 percent confidence interval after adjustment for group sequential testing, 1.8 to 499; unadjusted P<0.001). Pain diminished and the ability to eat improved with thalidomide treatment. The adverse effects noted with thalidomide included somnolence and rash (7 patients each), and 6 of the 29 patients discontinued treatment because of toxicity. Thalidomide treatment increased HIV RNA levels (median increase, 0.42 log₁₀ copies per milliliter; increase with placebo, 0.05; P = 0.04). With thalidomide treatment there were unexpected increases in the plasma concentrations of TNF- and soluble TNF- receptors.

Conclusions Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection.

Source Information

From the Departments of Medicine, Bronx Veterans Affairs Medical Center and Mount Sinai School of Medicine, New York (J.M.J.); the Department of Stomatology, University of California at San Francisco, San Francisco (J.S.G., L.A.M.); the Statistical and Data Analysis Center, Harvard School of Public Health, Boston (J.S., M.C.); the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md. (N.K., L.F.); the Department of Medicine, University of California at Los Angeles, Los Angeles (J.L.F.); the Departments of Pathology (J.B.J.) and Medicine (A.W.W.), Johns Hopkins University School of Medicine, Baltimore; the Department of Medicine, University of Puerto Rico Medical School, San Juan (G.J.V.); and the Department of Medicine, University of North Carolina, Chapel Hill (D.A.W.).

Address reprint requests to Dr. Jacobson at the Bronx Veterans Affairs Medical Center, 130 W. Kingsbridge Rd., Bronx, NY 10468.

Full Text of this Article

Related Letters:

Thalidomide for Aphthous Ulcers in HIV Infection
Birnkrant D., Jacobson J. M., Greenspan J. S., Spritzler J.
Extract | Full Text  
N Engl J Med 1997; 337:1086-1087, Oct 9, 1997. Correspondence

This article has been cited by other articles:

• Hwang, S. H., Rait, A., Pirollo, K. F., Zhou, Q., Yenugonda, V. M., Chinigo, G. M., Brown, M. L., Chang, E. H. (2008). Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Molecular Cancer Therapeutics 7: 559-568 [Abstract] [Full Text]  
• Tabata, C., Tabata, R., Kadokawa, Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T., Kubo, H. (2007). Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J. Immunol. 179: 708-714 [Abstract] [Full Text]  
• Thornhill, M. H., Baccaglini, L., Theaker, E., Pemberton, M. N. (2007). A Randomized, Double-blind, Placebo-Controlled Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis. Arch Dermatol 143: 463-470 [Abstract] [Full Text]  
• Henry, W. K., Tebas, P., Lane, H. C. (2006). Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.. JAMA 296: 1523-1525 [Full Text]  
• Scully, C. (2006). Clinical practice. Aphthous ulceration.. NEJM 355: 165-172 [Full Text]  
• Robinson, P.G. (2006). Implications of HIV Disease for Oral Health Services. ADR 19: 73-79 [Abstract] [Full Text]  
• Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]  
• Moutsopoulos, N M, Angelov, N, Sankar, V, Leakan, R A, Pillemer, S, Wahl, S M (2006). Immunological consequences of thalidomide treatment in Sjogren's syndrome. Ann Rheum Dis 65: 112-114 [Abstract] [Full Text]  
• (2005). Additional Information. JAMA 294: E1-E3 [Full Text]  
• Chintagumpala, M., Blaney, S. M., Bomgaars, L. R., Aleksic, A., Kuttesch, J. F., Klenke, R. A., Berg, S. L. (2004). Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer. JCO 22: 4394-4400 [Abstract] [Full Text]  
• Calabrese, L H, Zein, N, Vassilopoulos, D (2004). Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63: ii18-ii24 [Abstract] [Full Text]  
• Maurer, T., Poncelet, A., Berger, T. (2004). Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus-Infected Subjects: Efficacy and Risk of Neuropathy. Arch Dermatol 140: 845-849 [Abstract] [Full Text]  
• Kumar, S., Witzig, T. E., Rajkumar, S. V. (2004). Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. JCO 22: 2477-2488 [Abstract] [Full Text]  
• Gee, M. S., Makonnen, S., al-Kofahi, K., Roysam, B., Payvandi, F., Man, H.-W., Muller, G. W., Lee, W. M. F. (2003). Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition. Cancer Res. 63: 8073-8078 [Abstract] [Full Text]  
• Nasca, M. R, Micali, G., Cheigh, N. H, West, L. E, West, D. P (2003). Dermatologic and Nondermatologic Uses of Thalidomide. The Annals of Pharmacotherapy 37: 1307-1320 [Abstract] [Full Text]  
• Gordon, J N, Goggin, P M (2003). Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79: 127-132 [Abstract] [Full Text]  
• Mohty, M., Stoppa, A.-M., Blaise, D., Isnardon, D., Gastaut, J.-A., Olive, D., Gaugler, B. (2002). Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J. Leukoc. Biol. 72: 939-945 [Abstract] [Full Text]  
• Baughman, R. P., Judson, M. A., Teirstein, A. S., Moller, D. R., Lower, E. E. (2002). Thalidomide for Chronic Sarcoidosis*. Chest 122: 227-232 [Abstract] [Full Text]  
• Eisen, T. (2002). Thalidomide in Solid Malignancies. JCO 20: 2607-2609 [Full Text]  
• Majumdar, S., Lamothe, B., Aggarwal, B. B. (2002). Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J. Immunol. 168: 2644-2651 [Abstract] [Full Text]  
• Steins, M. B., Padro, T., Bieker, R., Ruiz, S., Kropff, M., Kienast, J., Kessler, T., Buechner, T., Berdel, W. E., Mesters, R. M. (2002). Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99: 834-839 [Abstract] [Full Text]  
• Fujita, J., Mestre, J. R., Zeldis, J. B., Subbaramaiah, K., Dannenberg, A. J. (2001). Thalidomide and Its Analogues Inhibit Lipopolysaccharide-mediated Induction of Cyclooxygenase-2. Clin. Cancer Res. 7: 3349-3355 [Abstract] [Full Text]  
• Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A. D., Goldschmidt, H. (2001). High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res. 7: 2675-2681 [Abstract] [Full Text]  
• Vincent Rajkumar, S., Kyle, R. A. (2001). Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 19: 3593-3595 [Full Text]  
• Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., Anderson, K. C. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216 [Abstract] [Full Text]  
• Karim, M Y, Ruiz-Irastorza, G, Khamashta, M A, Hughes, G R. (2001). Update on therapy -- thalidomide in the treatment of lupus. Lupus 10: 188-192 [Abstract]  
• Garcia-Lorda, P., Serrano, P., Jimenez-Exposito, M. J., Fraile, J., Bullo, M., Alonso, C., Bonada, A., Viciana, P., Garcia Luna, P. P., Salas-Salvado, J. (2000). Cytokine-Driven Inflammatory Response Is Associated with the Hypermetabolism of AIDS Patients with Opportunistic Infections. JPEN J Parenter Enteral Nutr 24: 317-322 [Abstract]  
• Verbon, A., Juffermans, N. P., Speelman, P., van Deventer, S. J. H., ten Berge, I. J. M., Guchelaar, H.-J., van der Poll, T. (2000). A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans. Antimicrob. Agents Chemother. 44: 2286-2290 [Abstract] [Full Text]  
• Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L., Pluda, J. M., Crawford, J. G., Yamauchi, H., Isaacs, C., Hanfelt, J., Tefft, M., Flockhart, D., Johnson, M. D., Hawkins, M. J., Lippman, M. E., Hayes, D. F. (2000). Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. JCO 18: 2710-2717 [Abstract] [Full Text]  
• Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., Whitby, D., Goedert, J. J., Yarchoan, R. (2000). Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. JCO 18: 2593-2602 [Abstract] [Full Text]  
• Fine, H. A., Figg, W. D., Jaeckle, K., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A., Black, P. M., Kaplan, R., Pluda, J. M., Yung, W. K. A. (2000). Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas. JCO 18: 708-708 [Abstract] [Full Text]  
• Hollis, S., Campbell, F. (1999). What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319: 670-674 [Abstract] [Full Text]  
• OLLIVIER, S, BONNET, J, LEMANN, M, COFFIN, J-C, MODIGLIANI, R, JIAN, R, BERTHEAU, P, FLEJOU, J-F (1999). Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment. Gut 45: 463-464 [Full Text]  
• Corcoran, C., Grinspoon, S. (1999). Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome. NEJM 340: 1740-1750 [Full Text]  
• Shek, L. P.-C., MD, Y. S. L., Lee, B. W., Lehman, T. J. A. (1999). Thalidomide Responsiveness in an Infant With Behcet's Syndrome. Pediatrics 103: 1295-1297 [Abstract] [Full Text]  
• Schuld, A., Mullington, J., Hermann, D., Hinze-Selch, D., Fenzel, T., Holsboer, F., Pollmacher, T. (1999). Effects of granulocyte colony-stimulating factor on night sleep in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 276: R1149-R1155 [Abstract] [Full Text]  
• Jason, J., Archibald, L., McDonald, L. C., Hart, W. M., Rheanppumikankit, S., Tansuphwaswadikul, S., Byrd, M. G., Larned, J., Han, A., Green, T. A., Jarvis, W. R. (1999). Immune Determinants of Organism and Outcome in Febrile Hospitalized Thai Patients with Bloodstream Infections. CVI 6: 73-78 [Abstract] [Full Text]  
• Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., Dalgleish, A. G. (1998). CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-{alpha} Production. J. Immunol. 161: 4236-4243 [Abstract] [Full Text]  
• Clarke, M., Chalmers, I. (1998). Discussion Sections in Reports of Controlled Trials Published in General Medical Journals: Islands in Search of Continents?. JAMA 280: 280-282 [Abstract] [Full Text]  
• Haslett, P. A.J., Corral, L. G., Albert, M., Kaplan, G. (1998). Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset. JEM 187: 1885-1892 [Abstract] [Full Text]  
• (1998). Clinical Pharmacology of Thalidomide. AIDS Clin Care 1998: 2-2 [Full Text]  
• Birnkrant, D., Jacobson, J. M., Greenspan, J. S., Spritzler, J. (1997). Thalidomide for Aphthous Ulcers in HIV Infection. NEJM 337: 1086-1087 [Full Text]  
• (1997). Thalidomide for Oral Aphthous Ulcers in HIV Infection. Journal Watch Dermatology 1997: 8-8 [Full Text]  
• (1997). Thalidomide and Oral Aphthous Ulcers. AIDS Clin Care 1997: 5-5 [Full Text]  
• (1997). THALIDOMIDE TREATS APHTHOUS ULCERS IN AIDS. JWatch General 1997: 2-2 [Full Text]